Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: Mechanisms, clinical significance, and avoidance

被引:79
作者
Chan, TYK
机构
[1] Department of Clinical Pharmacology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories
关键词
D O I
10.1177/106002809502901214
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO review the mechanisms and clinical significance of adverse interactions between warfarin and nonsteroidal antiinflammatory drugs (NSAIDs) and discuss how these interactions can be avoided. DATA SOURCES: Previous studies of interactions between warfarin and NSAIDs or reports of adverse interactions were identified from a MEDLINE search (1976 to present) and from the reference lists of pertinent articles. STUDY SELECTION AND DATA EXTRACTION: ALL articles were considered for inclusion in the review. Pertinent information was selected for discussion. DATA SYNTHESIS: All NSAIDs can prolong bleeding time by inhibiting platelet function. High-dose aspirin has a direct hypoprothrombinemic effect. Phenylbutazone and its analogs enhance the hypoprothrombinemic effect of warfarin through a pharmacokinetic interaction by inhibiting the hepatic metabolism of warfarin. Mefenamic acid also enhances the anticoagulant effect of warfarin, but the mechanism is not known. The clinical relevance of protein binding displacement in the interaction between warfarin and NSAIDs has been overstated, although a significant one may be more likely in the presence of high concentrations of NSAIDs in patients with slow elimination of warfarin (e.g., those with severe heart failure or impaired liver function). NSAIDs can induce gastrointestinal bleeding, which is likely to be more severe if warfarin is also given. CONCLUSIONS: The combined use of warfarin and NSAIDs is generally discouraged because of the increased risk of bleeding in these patients. In patients receiving warfarin who also require NSAIDs, phenylbutazone and its analogs, high-dose aspirin, mefenamic acid, excessive use of topical methyl salicylate, and NSAIDs that are associated with a higher risk of bleeding peptic ulcers should be avoided. Patients should be closely monitored for anticoagulant control and bleeding complications during the combined use of warfarin and NSAIDs.
引用
收藏
页码:1274 / 1283
页数:10
相关论文
共 89 条
  • [11] ADVERSE INTERACTION BETWEEN WARFARIN AND INDOMETHACIN
    CHAN, TYK
    LUI, SF
    CHUNG, SY
    LUK, S
    CRITCHLEY, JAJH
    [J]. DRUG SAFETY, 1994, 10 (03) : 267 - 269
  • [12] ADVERSE REACTIONS TO DRUGS AS A CAUSE OF ADMISSIONS TO A GENERAL TEACHING HOSPITAL IN HONG-KONG
    CHAN, TYK
    CHAN, JCN
    TOMLINSON, B
    CRITCHLEY, JAJH
    [J]. DRUG SAFETY, 1992, 7 (03) : 235 - 240
  • [13] CHAN TYK, 1995, IN PRESS PHARMACOEPI
  • [14] BINDING OF NONSTEROIDAL ANTI-INFLAMMATORY AGENTS AND THEIR EFFECT ON BINDING OF RACEMIC WARFARIN AND ITS ENANTIOMERS TO HUMAN-SERUM ALBUMIN
    DIANA, FJ
    VERONICH, K
    KAPOOR, AL
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (03) : 195 - 199
  • [15] A COMPARISON OF ISOMERS OF WARFARIN
    EBLE, JN
    WEST, BD
    LINK, KP
    [J]. BIOCHEMICAL PHARMACOLOGY, 1966, 15 (07) : 1003 - &
  • [16] ABSENCE OF INTERACTION BETWEEN TENOXICAM AND WARFARIN
    EICHLER, HG
    JUNG, M
    KYRLE, PA
    ROTTER, M
    KORN, A
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 42 (02) : 227 - 229
  • [17] EISEN MJ, 1964, JAMA-J AM MED ASSOC, V189, P64
  • [18] CONCOMITANT ETODOLAC AFFECTS NEITHER THE UNBOUND CLEARANCE NOR THE PHARMACOLOGICAL EFFECT OF WARFARIN
    ERMER, JC
    HICKS, DR
    WHEELER, SC
    KRAML, M
    JUSKO, WJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (03) : 305 - 316
  • [19] FITZGERALD DE, 1985, NABUMETONE NOVEL ANT, V69, P47
  • [20] PROLONGATION OF PROTHROMBIN TIME AND SEVERE GASTROINTESTINAL-BLEEDING ASSOCIATED WITH COMBINED USE OF WARFARIN AND KETOPROFEN
    FLESSNER, MF
    KNIGHT, H
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (03): : 353 - 353